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Previewsthe AvrPphB prodomain in its secretion
process, the cellular location of pro-
domain removal, and how the prodo-
main removal effects protease activity.
AvrPphB is a 3.3 nm 35 kDa pro-protease
that is known to autocatalytically cleave to
a 28 kDa isoform. Previous work has
shown that the protease is injected into
the host cell through a type III secretion
system (TTSS), after which the protein is
targeted to the host membrane and
cleaves host kinases (Nimchuk et al.,
2000; Dowen et al., 2009). A major ques-
tion in the regulation of this process is if
the cleavage of the AvrPphB prodomain
occurs in the bacteria or in the host cell.
It is widely assumed that the cleavage
must occur in the bacteria, because the
type III pilus is estimated at a width
smaller than 2.5 nm, which is likely too
small for the full AvrPphB to traverse. To
answer this fundamental question, the
authors made use of both biological and
chemical methodologies. First, using
FH11, they found that AvrPphb secretion
is TTSS dependent by detecting activity
in both bacteria and supernatant after
TTSS induction. Next, the authors created
an AvrPphB mutant lacking the prodo-
main and found that the protease is found
active only in the bacteria and is no longer
found in the secreted medium, demon-138 Chemistry & Biology 20, February 21, 201strating that the prodomain is necessary
for AvrPphB translocation (Figure 1B).
Lastly, they designed an AvrPphB with
a mutation in the prodomain cleavage
site and found that while the protein is still
able to bind to the ABP FH11 and
undergoes secretion into the medium, it
is no longer able to activate HR in the
host plant cell. Taken together, these
results surprisingly show that the prodo-
main is necessary for translocation of
the protease through the pilus, and its
removal is required to trigger plant cell
hypersensitivity.
In contrast to fluorogenic substrate
probes that undergo cleavage and pro-
duce a fluorescent signal in the sur-
rounding area, covalently binding ABPs
provide the important advantage of
specifically attaching to the protease.
This feature allows for accurate and
precise analysis of the protein’s location
and the identification of the protease
responsible for the cleavage. The applica-
tion of ABPs to fundamental biological
questions enhances analytical capabil-
ities and dramatically advances our
understanding of the dynamic involved
in protease regulation. Lu et al. (2013)
successfully merge the design of a novel
ABP with a challenging biological system
and, in doing so, create an outstanding3 ª2013 Elsevier Ltd All rights reservedexample for the connection of chemical
application and biological research. Fur-
ther research should make use of this
interdisciplinary model in hopes of
advancing our understanding of the com-
plexity of protease regulation in bacterial
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In this issue of Chemistry & Biology, Dalli and colleagues report the chemical structures of resolvin D3 (RvD3)
and aspirin-triggered RvD3, derived from the u3-fatty acid docosahexaenoic acid. These compounds have
a specific temporal appearance within inflammation resolution and display anti-inflammatory and
proresolving properties. Together, the results will help design new resolvin mimetics, potential resolution
agonists with anti-inflammatory properties.Acute inflammation is the host’s response
to injury and brings together an army
of immune cells in a tightly controlled,
time- and context-dependent manner to
combat the intruders. In addition to direct
engulfment and killing of the enemy, thesecells will release a plethora of factors
that will further drive and coordinate the
inflammatory response and prepare the
tissue for subsequent repair. Among
these factors are lipid mediators, in
particular the eicosanoids, typified byprostaglandins, thromboxane, and leuko-
trienes (LTs) (Samuelsson, 1983). If the
acute inflammation does not resolve
properly, it may develop into a persistent
state, i.e., chronic inflammation, a hall-
mark of many endemic diseases such as
Figure 1. Biosynthesis of RvD3 and AT-RvD3
Cells, such as macrophages, eosinophils, and neutrophils, that are rich in 15-LOX and 5-LOX activity
convert DHA into RvD3. In the presence of acetylated COX-2, AT-RvD3, the 17R-epimer of RvD3, is
formed (hydroxyl groups at C17 are highlighted in pink).
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Previewsrheumatoid arthritis, inflammatory bowel
disease, atherosclerosis, and asthma.
Until recently, the resolution phase of
inflammationwas believed to be a passive
process reflecting the gradual disappear-
ance of proinflammatory cells and media-
tors. However, it has now become evident
that resolution is an active process, and
Serhan et al. (2008) have found that
several families of specialized lipidmedia-
tors are involved in this process. Their
work began with the discovery of lipoxins,
trihydroxylated tetraene derivatives of
arachidonic acid, initially thought to have
selective proinflammatory properties
(Serhan et al., 1984). Further studies
uncovered the aspirin-triggered lipoxins,
thebiosynthesis ofwhich involves genera-
tion of 15R-HETE by acetylated cyclooxy-
genase (COX) type 2 (Cla`ria and Serhan,
1995). Since polyunsaturated u3 fatty
acids have well documented anti-inflam-
matory actions, a systems approach
with resolving inflammatory exudates
revealed that eicosapentaenoic acid and
docosahexaenoic acid (DHA) are con-
verted into oxygenated products withproresolving properties. As a conse-
quence, the resolvins, protectins, and,
most recently, maresins were identified,
each with their own characteristic profile
of bioactivities (SerhanandPetasis, 2011).
In this issue of Chemistry & Biology,
Dalli et al. (2013) have used a classical
strategy to determine the complete
stereochemistry and double bond geom-
etry of RvD3 and its aspirin-triggered
counterpart, AT-RvD3. In much the
same way as the chemistry and struc-
ture-activity relationships of the LTs
were once elucidated (Samuelsson,
1983), Dalli et al. (2013) isolated biologi-
cally generated materials and compared
their biophysical and biological properties
with chemically defined compounds
obtained by total organic synthesis. The
authors conclude that RvD3 has the
absolute structure 4S, 11R, 17S-trihy-
droxydocosa-5Z, 7E, 9E, 13Z, 15E, 19Z-
hexaenoic acid and that AT-RvD3 is the
17R-epimer of this molecule. The biosyn-
thetic pathways from DHA to RvD3 and
AT-RvD3 are not fully understood but
seem to involve initial oxygenationChemistry & Biology 20, February 21, 2013catalyzed by 15-lipoxygenase (LOX) or
COX-2 acetylated by aspirin, respec-
tively, followed by 5-LOX-catalyzed oxy-
genation and epoxide formation (Figure 1).
The epoxide hydrolysis taking place in the
last step brings to mind the leukotriene
(LT)A4 hydrolase-catalyzed conversion of
LTA4 into LTB4 (Haeggstro¨m and Funk,
2011). In fact, the 5Z, 7E, 9E double
bond geometry of RvD3 resembles the
6Z, 8E, 10E conjugated triene of LTB4,
suggesting the involvement of a selective
hydrolase in RvD3 biosynthesis.
Applying LC-MS on exudates from
a mouse model of self-limited resolving
skin inflammation (Serhan et al., 2008),
the authors show that RvD3 appears in
a specific temporal window within the
inflammation-resolution process. Unlike
the proinflammatory prostaglandins and
LTs that appear early (6 hr), RvD3
synthesis does not take off until after
24 hr, peaks at 48 hr, and is still abundant
after 72 hr. This temporal profile with
persistent formation at late time points
makes RvD3 unique among other tested
resolvins and suggests that this lipid
mediator plays specific roles in the resolu-
tion and healing of inflammation. Accord-
ingly, Dalli et al. (2013) found that RvD3
and AT-RvD3 exhibit distinct anti-inflam-
matory and proresolving properties.
Thus, when injected intraperitoneally in
a mouse model of zymosan-induced peri-
tonitis, both molecules inhibit neutrophil
transmigration, and in exudates, levels of
IL-6 were decreased in parallel with
increased levels of IL-10. Furthermore,
when administered systemically, RvD3
and AT-RvD3 reduce the levels of pro-
inflammatory eicosanoids, specifically
COX-derived thromboxane A2 and pros-
taglandin D2 as well as the 5-LOX metab-
olite LTB4. When tested for their prore-
solving properties, RvD3 and AT-RvD3
were found to stimulate human macro-
phage phagocytosis as well as efferocy-
tosis, actions that will help clear the
inflamed tissue from noxious agents and
apoptotic cells, events key to resolution.
RvD3 and AT-RvD3 are members of a
growing family of specialized proresolving
lipid mediators, including lipoxins, resol-
vins, protectins, and maresins. The mole-
cules are detected in small quantities,
which is mirrored by their exceptional bio-
logical potency, usually in the pM range
(Serhan et al., 2008). For some of them, G
protein coupled receptors have beenª2013 Elsevier Ltd All rights reserved 139
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Previewsidentified (ALX/FPR2, ChemR23, BLT1,
and gpr32); but, clearly, elucidation of the
signaling pathways of these lipidmediators
will be a major future challenge. In any
event, the powerful anti-inflammatory and
proresolving properties of resolvins hold
therapeutic promise, underpinned by the
previous success story of eicosanoid-
modifying drugs (Samuelsson, 2012). To
fully explore the pharmacological utility of
such molecules, the precise molecular
signatures that confer bioactivity have to
be elucidated, as now achieved with RvD3
and AT-RvD3. In addition to its antipyretic
and analgesic effects, it is well established
that aspirin, due to its blockade of platelet
thromboxane synthesis (Hamberg et al.,
1975), exerts antihemostatic and antith-
rombotic effects, and low-dose aspirin is
currently used for prophylaxis of myocar-
dial infarction and stroke. Aspirin has addi-Figure 1. R
Mechanism
Inhibitory C
The gene tet
140 Chemistry & Biology 20, February 21, 201tional beneficial effects, and the possible
role of this drug for prevention of a larger
spectrum of diseases, including cancer, is
currently being explored. AT-RvD3 and
other aspirin-triggered resolvins are likely
to be of importance in such contexts.
To use a metaphor proresolving lipid
mediators can be viewed as members of
an orchestra, where the cellular conductor
creates a resolution symphony specifically
tuned for the inflamed tissues to return to
homeostasis. With this perspective, Dalli
et al. (2013) have now defined two new
instruments RvD3 and AT-RvD3.
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The TetR family ofmicrobial transcription factors directly control the expression of a diverse range of genes in
bacteria by sensing specific ligands. In this issue of Chemistry & and Biology, Cuthbertson and colleagues
used phylogenomics to guide the identification of TetR-like protein cognate ligands and revealed a novel
inducible antibiotic resistance mechanism.TetR-family regulators (TFRs) are proteins
constitutedof twodomains:aDNA-binding
helix-turn-helix domain that is able to inter-
act with specific DNA motifs in operatora Sub-
.sites and a ligand binding (or
receptor) domain that
interacts with cognate small
organic molecules (Ramos
et al., 2005; Yu et al., 2010).
TFRs typically act as homodi-
meric transcriptional re-
pressors and control the
expression of diverse genes,
such as those that confer
antibiotic resistance (i.e.,
efflux pumps and modifyingenzymes), but also genes that direct the
biosynthesis of natural products and
morphogenesis or biofilm formation, to
mention a few. TFRs are widespread inbacteria and many of them repress the
transcription of genes that confer resis-
tance to the molecule sensed by the TFR
itself (Ramos et al., 2005). For instance,TetR senses the antibiotic
tetracycline and represses
the expression of tetA, which
encodes for a tetracycline
efflux pump, in the absence
of tetracycline as shown in
Figure 1 (Orth et al., 2000).
The set of genes regulated
by TFRs is only known in
a limited number of cases. In
some systems, the regulatory
network is relatively complex
